In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2379-2387

  Urbina, Julio A ^a   Concepcion, Juan Luis ^b   Caldera, Aura ^a   Payares, Gilberto ^c   Sanoja, Cristina ^c   Otomo, Takeshi ^d   Hiyoshi, Hironobu ^d  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b FACULTAD DE CIENCIAS   (Venezuela)

^c FACULTAD DE CIENCIAS   (Venezuela)

^d EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[2 BENZYL 6 (3 HYDROXY 4 METHOXYPYRROLIDIN 1 YL)PYRIDIN 3 YL]ETHYNYL]QUINUCLIDIN 3 OL; 3 [[2 BENZYL 6 (3 METHOXYPROPYLOXY)PYRIDINE 3 YL]ETHYNYL]QUINUCLIDIN 3 OL; E 5700; ER 119884; QUINUCLIDINE DERIVATIVE; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG TARGETING; ENZYME INHIBITION; EPIMASTIGOTE; HOST CELL; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARASITE SURVIVAL; PARASITEMIA; PRIORITY JOURNAL; PROTEIN TARGETING; TRYPANOSOMA CRUZI;

ANIMALS; CELL DIVISION; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FEMALE; KINETICS; LIPID METABOLISM; MICE; PYRIDINES; QUINUCLIDINES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 3042570789     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2379-2387.2004     Document Type: Article

References (36)

1. Bergstrom, J. D., C. Dufresne, G. F. Bills, M. Nallin-Omstead, and K. Byrne. 1995. Discovery, synthesis and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Annu. Rev. Microbiol. 49:607-639.
2. Blagg, B. S., M. B. Jarstfer, D. H. Rogers, and C. D. Poulter. 2002. Recombinant squalene synthase. A mechanism for the rearrangement of presqualene diphosphate to squalene. J. Am. Chem. Soc. 124:8846-8853.
3. Brown, D. A., and E. London. 2000. Structure and function of sphingolipid-and cholesterol-rich membrane rafts. J. Biol. Chem. 275:17221-17224.
4. Brown, G. R., A. J. Foubister, S. Freeman, P. J. Harrison, M. C. Johnson, K. B. Mallion, J. McCormick, F. McTaggart, A. C. Reid, G. J. Smith, and M. J. Taylor. 1996. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J. Med. Chem. 39:2971-2979.
5. De Maio, A., and J. A. Urbina. 1984. Trypanosoma (Schizotrypanum) cruzi: terminal oxidases in two growth phases in vitro. Acta Cient. Venez. 35:136-141.
6. Goldstein, J. L., and M. S. Brown. 2001. The cholesterol quartet. Science 292:1310-1312.
7. Hudson, L., F. Grover, W. E. Gutteridge, R. A. Klein, W. Peters, R. A. Neal, M. A. Miles, M. T. Scott, R. Nourish, and B. P. Ager. 1983. Suggested guidelines for work with live Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 77:416-419.
8. Ishihara, T., H. Kakuta, H. Moritani, T. Ugawa, S. Sakamoto, S. Tsukamoto, and I. Yanagisawa. 2003. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg. Med. Chem. 11:2403-2414.
9. Ishihara, T., H. Kakuta, H. Moritani, T. Ugawa, S. Sakamoto, S. Tsukamoto, and I. Yanagisawa. 2003. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg. Med. Chem. 11:3735-3745.
10. Jarstfer, M. B., D. L. Zhang, and C. D. Poulter. 2002. Recombinant squalene synthase. Synthesis of non-head-to-tail isoprenoids in the absence of NADPH. J. Am. Chem. Soc. 124:8834-8845.
11. McTaggart, F., G. R. Brown, R. G. Davidson, S. Freeman, G. A. Holdgate, K. B. Mallion, D. J. Mirrlees, G. J. Smith, and W. H. J. Ward. 1996. Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines. Biochem. Pharmacol. 51:1477-1487.
12. Menys, V. C., and P. N. Durrington. 2003. Squalene synthase inhibitors. Br. J. Pharmacol. 139:881-882.
13. 31P NMR spectroscopy of Trypanosoma brucei, Trypanosoma cruzi and Leishmania major: evidence for high levels of condensed inorganic phosphates. J. Biol. Chem. 275:28356-28362.
14. Poulter, C. D. 1990. Biosynthesis of non-head-to tail terpenes. Formation of 1′-1 and 1′-3 linkages. Acc. Chem. Res. 23:70-77.
15. Radisky, E. S., and C. D. Poulter. 2000. Squalene synthase: steady-state, pre-steady state and isotope-trapping studies. Biochemistry 39:1748-1760.
16. Ruiz, F. A., C. O. Rodrigues, and R. Docampo. 2001. Rapid changes in polyphosphate content within acidocalcisomes in response to cell growth, differentiation and environmental stress in Trypanosoma cruzi. J. Biol. Chem. 276:26114-26121.
17. Simons, K., and E. Ikonen. 1997. Functional lipid rafts in cell membranes. Nature 387:569-571.
18. Tait, R. M. 1992. Development of a radiometric spot-wash assay for squalene synthase. Anal. Biochem. 203:310-316.
19. Ugawa, T., H. Kakuta, H. Moritani, O. Inagaki, and H. Shikama. 2003. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br. J. Pharmacol. 139:140-146.
20. Ugawa, T., H. Kakuta, H. Moritani, K. Matsuda, T. Ishihara, M. Yamaguchi, S. Naganuma, Y. Iizumi, and H. Shikama. 2000. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglycerides in several animal species. Br. J. Pharmacol. 131:63-70.
21. Urbina, J. A. 2002. Chemotherapy of Chagas disease. Curr. Pharm. Des. 8:287-295.
22. Urbina, J. A. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 117:S91-S99.
23. Urbina, J. A. 2003. Rational approaches to specific chemotherapy of Chagas disease, p. 127-135. In K. M. Tyler and M. A. Miles (ed.), World class parasites, vol. 7. American trypanosomiasis. Kluwer Academic Publishers, Boston, Mass.
24. Urbina, J. A. 2001. Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. 14:733-741.
25. Urbina, J. A. 2000. Sterol biosynthesis inhibitors for Chagas' disease. Curr. Opin. Anti-infect. Investig. Drugs 2:40-46.
26. Urbina, J. A., J. L. Concepcion, A. Montalvetti, J. B. Rodriguez, and R. Docampo. 2003. Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob. Agents Chemother. 47:2047-2050.
27. Urbina, J. A., J. L. Concepcion, S. Rangel, G. Visbal, and R. Lira. 2002. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol. 125:35-45.
28. Urbina, J. A., and R. Docampo. 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19:495-501.
29. Urbina, J. A., B. Moreno, S. Vierkotter, E. Oldfield, G. Payares, C. Sanoja, B. N. Bailey, W. Yan, D. A. Scott, S. N. J. Moreno, and R. Docampo. 1999. Trypanosoma cruzi contains major pyrophosphate stores and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J. Biol. Chem. 274:33609-33615.
30. Urbina, J. A., G. Payares, L. M. Contreras, A. Liendo, C. Sanoja, J. Molina, M. Piras, R. Piras, N. Perez, P. Wincker, and D. Loebenberg. 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1771-1777.
31. Urbina, J. A., G. Payares, J. Molina, C. Sanoja, A. Liendo, K. Lazardi, M. M. Piras, R. Piras, N. Perez, P. Wincker, and J. F. Ryley. 1996. Cure of short-and long-term experimental Chagas disease using D0870. Science 273:969-971.
32. Urbina, J. A., G. Payares, C. Sanoja, R. Lira, and A. J. Romanha. 2003. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 21:27-38.
33. Urbina, J. A., G. Payares, C. Sanoja, J. Molina, R. Lira, Z. Brener, and A. J. Romanha. 2003. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents. 21:39-48.
34. Ward, W. H. J., G. A. Holdgate, S. Freeman, F. McTaggart, P. A. Girdwood, R. G. Davidson, K. B. Mallion, G. R. Brown, and M. A. Eakin. 1996. Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine. Biochem. Pharmacol. 51:1489-1501.
35. Watson, N. S., and P. A. Procopiou. 1996. Squalene synthase inhibitors: their potential as hypocholesterolemic agents. Prog. Med. Chem. 33:331-378.
36. World Health Organization. 2002. Control of Chagas disease, p. 1-109. In Technical Report Series no. 905. World Health Organization, Geneva, Switzerland.